Home Overview Press Room Blog Publications For Students about us
Search

About Egg Retrieval


Scientists working to perform research cloning require large numbers of women's eggs for their efforts. Egg retrieval is invasive, time-consuming, uncomfortable, and—most important—puts women at risk of significant adverse reactions.

In order to procure eggs, researchers give women hormonal drugs to first "shut down" and then "hyperstimulate" their ovaries to produce more eggs than normal. These eggs are then surgically extracted.

Egg retrieval for assisted reproduction has been conducted for several decades, but there is inadequate data on its risks. Follow-up studies on long-term risks are particularly lacking; those that do exist are inconclusive.

Short-term reactions to one commonly used "shut-down" drug include severe joint pain, difficulty breathing, chest pain, depression, amnesia, hypertension, and asthma. The drugs used to stimulate multiple egg production can cause ovarian hyperstimulation syndrome (OHSS), which is often a mild reaction but which can become serious enough to require hospitalization and, rarely, to cause death.

Some women's health advocates and others have questioned whether researchers should ask women to expose themselves to these risks, especially in light of the early and speculative stage of cloning research. Proposals to pay women to provide eggs for research remain controversial, as this practice could tempt economically vulnerable women to take risks they otherwise would avoid.



Designer babies: an ethical horror waiting to happen?by Philip BallThe Guardian January 8th, 2017A perfectly feasible 10-20% improvement in health via PGD, added to the comparable advantage that wealth already brings, could lead to a widening of the health gap between rich and poor, both within a society and between nations.
Why tech offers better fertility benefits than other industries[cites CGS's Marcy Darnovsky]by Alison DeNiscoTech RepublicDecember 21st, 2016The benefits are part of the current talent war for engineers and other professionals. Tech workers should be cautious about using the procedures.
We Launched a New Website! Surrogacy360by Kiki Zeldes, Biopolitical Times guest contributorDecember 14th, 2016Surrogacy360 provides accurate information and resources, free of commercial interest, for people considering surrogacy outside the United States.
Biopolitical News of 2016by Pete Shanks, Leah Lowthorp & Marcy DarnovskyBiopolitical TimesDecember 13th, 2016We highlight 2016’s trends in and top news stories about human biotech developments.
'No solid evidence' for IVF add-on successby Deborah CohenBBC PanoramaNovember 28th, 2016A year-long study finds that nearly all costly add-on treatments offered by UK fertility clinics are unreliable, misleading, and risky.
Increase in IVF complications raises concerns over use of fertility drugsby Hannah DevlinThe Guardian [US]November 13th, 2016Stronger drugs used to harvest more eggs could also be linked to a 40% increase in cases of ovarian hyperstimulation syndrome.
ACCC puts IVF clinics 'on notice' over misleading success rate claimsby Madeleine MorrisABC [Australia]November 13th, 2016Some major Australian fertility clinics changed confusing marketing messages on their websites after a consumer group's investigation documented their misleading claims.
A Call to Protect the Health of Women Who Donate Their Eggsby Judy Norsigian and Dr. Timothy R.B. JohnsonThe Women’s Health ActivistNovember 12th, 2016The egg market is growing, yet long-term safety data does not exist to enable donors to make informed choices about selling their eggs.
Cambodia bans booming commercial surrogacy industryby AFPChannel News AsiaNovember 3rd, 2016A government edict makes Cambodia the latest country to ban commercial surrogacy after prohibitions in other parts of the globe sparked a local boom in business.
The Cash Cow in 'Fertility' Medicineby Pamela M TsigdinosHealthcare in AmericaOctober 23rd, 2016The unregulated fertility industry often fails to disclose: lucrative profits, poor outcomes, emotional burdens, and medical risks.
Displaying 1-10 of 850  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760